News Releases Year None20242023202220212020201920182017 Apr 9, 2024 ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”) Read more Mar 7, 2024 ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Read more Mar 5, 2024 ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting Read more Jan 3, 2024 ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference Read more
